Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000950103-25-001086·Revance Therapeutics, Inc.
Schedule 13D ownership disclosure
REVANCE THERAPEUTICS INC
Common Stock, par value $0.001 per share · CUSIP: 761330109
Event date: 2025-01-30
- Filing-level shares
- 6,550,800.00
- Percent of class
- 6.2%
- Teoxane SAReported CIK 0001992112
Shares: 6,550,800.00 · Class: 6.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950103-25-001086
- Form type
- SCHEDULE 13D/A
- Filer
- Revance Therapeutics, Inc.
- CIK
- CIK 1479290
- Filed
- Jan 30, 2025
- Reporting period
- Jan 30, 2025
- Description
- Schedule 13D beneficial ownership